Literature DB >> 26874637

Atypical femoral fracture following zoledronic acid treatment.

Baybars Ataoğlu1, Ahmet Yiğit Kaptan, Toygun Kağan Eren, Ali Ekber Yapar, Ahmet Fırat Berkay.   

Abstract

A 68-year-old female patient admitted to our clinic with right anterior thigh pain ongoing for six months and which increased in last two months. The patient had no trauma history. The patient had been followed-up for 15 years because of osteoporosis and administrated alendronate and ibandronate treatment for 10 years. Patient had three shots of zoledronate once a year during the last three years. Her pain was increasing when she was walking. Physical examination revealed pain in her right thigh. Radiogram showed thickened lateral cortex of the subtrochanteric area. Magnetic resonance imaging also showed thickening and edema of the same area. These images were correlated with atypical fracture in right femoral subthrochanteric zone. Dual energy X-ray absorptiometry revealed that T score was -3.3 in lumbar region and -2.5 in femoral neck. Zoledronate treatment was ended. Prophylactic surgical fixation was performed with titanium elastic nails.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26874637     DOI: 10.5606/ehc.2016.11

Source DB:  PubMed          Journal:  Eklem Hastalik Cerrahisi


  2 in total

1.  Ibandronate sodium and zoledronate sodium in the treatment of senile osteoporosis: efficacy, impact on quality of life and cost-effectiveness analysis.

Authors:  Shuang Liang; Shaozhen Hu; Hong Guo; Leilei Dong; Guoqiang Liu; Yang Liu
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

2.  Prior administration of vitamin K2 improves the therapeutic effects of zoledronic acid in ovariectomized rats by antagonizing zoledronic acid-induced inhibition of osteoblasts proliferation and mineralization.

Authors:  Bin Zhao; Wenqian Zhao; Yiqiang Wang; Zhao Zhao; Changfeng Zhao; Shue Wang; Chunzheng Gao
Journal:  PLoS One       Date:  2018-08-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.